The FDA’s Division of Drug Marketing, Advertising andCommunications issued 21 warning and untitled letters in 2008 – scarcely morethan the 20 letters the unit sent out in 2007.

As in 2007, 10 were “warning letters,” the remainder being ofthe somewhat less serious “untitled” variety.

In 2006, DDMAC issued 22 letters reprimanding drugmanufacturers for promotional materials deemed violative of the Food, Drug andCosmetics Act, typically for overstating efficacy and/or underplaying risks, but14 of those were warning letters.